 Robert McQueen
Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 30 | 2025 | 591 | 3.780 |
Why?
| | Negotiating | 3 | 2025 | 32 | 1.900 |
Why?
| | Quality-Adjusted Life Years | 12 | 2024 | 113 | 1.780 |
Why?
| | Models, Economic | 8 | 2025 | 58 | 1.360 |
Why?
| | Medicare | 3 | 2025 | 773 | 1.310 |
Why?
| | Diabetes Mellitus, Type 1 | 9 | 2025 | 3715 | 1.240 |
Why?
| | Drug Costs | 5 | 2025 | 106 | 1.190 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2024 | 641 | 1.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 7 | 2025 | 804 | 1.110 |
Why?
| | Patient-Centered Care | 2 | 2023 | 530 | 1.060 |
Why?
| | Health Expenditures | 3 | 2024 | 189 | 1.050 |
Why?
| | Genetic Therapy | 3 | 2025 | 297 | 1.010 |
Why?
| | Natalizumab | 4 | 2015 | 40 | 0.980 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 3 | 2015 | 76 | 0.970 |
Why?
| | Technology Assessment, Biomedical | 3 | 2022 | 33 | 0.940 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 445 | 0.930 |
Why?
| | Immunologic Factors | 3 | 2015 | 236 | 0.880 |
Why?
| | Reimbursement Mechanisms | 1 | 2025 | 85 | 0.880 |
Why?
| | Decision Support Techniques | 4 | 2022 | 421 | 0.870 |
Why?
| | Ovarian Neoplasms | 2 | 2020 | 565 | 0.850 |
Why?
| | Medicaid | 2 | 2025 | 435 | 0.840 |
Why?
| | Hemophilia B | 1 | 2023 | 61 | 0.810 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2025 | 190 | 0.800 |
Why?
| | Azetidines | 1 | 2022 | 43 | 0.780 |
Why?
| | Endometriosis | 1 | 2023 | 51 | 0.770 |
Why?
| | Asthma | 6 | 2023 | 2295 | 0.760 |
Why?
| | Hypercholesterolemia | 1 | 2022 | 106 | 0.730 |
Why?
| | Hemophilia A | 1 | 2023 | 139 | 0.730 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2024 | 2531 | 0.710 |
Why?
| | United States | 18 | 2025 | 14841 | 0.710 |
Why?
| | Anemia, Sickle Cell | 1 | 2025 | 270 | 0.700 |
Why?
| | Anticholesteremic Agents | 1 | 2022 | 153 | 0.690 |
Why?
| | Value-Based Purchasing | 1 | 2019 | 8 | 0.650 |
Why?
| | Academies and Institutes | 1 | 2019 | 53 | 0.630 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 115 | 0.610 |
Why?
| | Hypoglycemic Agents | 3 | 2024 | 1291 | 0.610 |
Why?
| | Patient Outcome Assessment | 1 | 2019 | 131 | 0.590 |
Why?
| | Health Care Costs | 2 | 2020 | 398 | 0.580 |
Why?
| | Biological Therapy | 1 | 2018 | 29 | 0.580 |
Why?
| | Atherosclerosis | 1 | 2022 | 415 | 0.580 |
Why?
| | Foodborne Diseases | 3 | 2024 | 57 | 0.560 |
Why?
| | Humans | 57 | 2025 | 137585 | 0.560 |
Why?
| | Telephone | 1 | 2018 | 173 | 0.530 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 1081 | 0.510 |
Why?
| | Health Benefit Plans, Employee | 1 | 2015 | 25 | 0.480 |
Why?
| | Blood Glucose | 4 | 2024 | 2186 | 0.450 |
Why?
| | Research Design | 4 | 2024 | 1139 | 0.440 |
Why?
| | Insulin | 1 | 2024 | 2409 | 0.420 |
Why?
| | Hypoglycemia | 2 | 2024 | 445 | 0.410 |
Why?
| | Cardiovascular Diseases | 2 | 2022 | 2111 | 0.400 |
Why?
| | Markov Chains | 4 | 2025 | 126 | 0.400 |
Why?
| | Mass Screening | 2 | 2024 | 1287 | 0.400 |
Why?
| | Anti-Asthmatic Agents | 4 | 2018 | 395 | 0.390 |
Why?
| | Lung Neoplasms | 1 | 2025 | 2526 | 0.370 |
Why?
| | Metformin | 1 | 2015 | 331 | 0.370 |
Why?
| | Immunotherapy, Adoptive | 3 | 2019 | 327 | 0.360 |
Why?
| | Female | 25 | 2025 | 73304 | 0.350 |
Why?
| | Medication Adherence | 1 | 2015 | 467 | 0.350 |
Why?
| | Insurance Claim Review | 2 | 2024 | 64 | 0.350 |
Why?
| | Cost of Illness | 4 | 2024 | 308 | 0.350 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2017 | 617 | 0.330 |
Why?
| | Severity of Illness Index | 3 | 2017 | 2828 | 0.330 |
Why?
| | Costs and Cost Analysis | 3 | 2020 | 213 | 0.330 |
Why?
| | Neoplasms | 2 | 2020 | 2671 | 0.290 |
Why?
| | Diabetes Mellitus | 1 | 2017 | 1040 | 0.290 |
Why?
| | Male | 21 | 2025 | 67762 | 0.290 |
Why?
| | Aged | 10 | 2025 | 23961 | 0.250 |
Why?
| | Drug Therapy, Combination | 4 | 2022 | 1066 | 0.250 |
Why?
| | Comparative Effectiveness Research | 2 | 2025 | 152 | 0.240 |
Why?
| | Colorado | 4 | 2025 | 4565 | 0.240 |
Why?
| | Adult | 17 | 2025 | 37929 | 0.240 |
Why?
| | Middle Aged | 16 | 2024 | 33479 | 0.230 |
Why?
| | Autoantibodies | 2 | 2025 | 1496 | 0.230 |
Why?
| | Syphilis | 1 | 2024 | 32 | 0.220 |
Why?
| | Omalizumab | 2 | 2023 | 51 | 0.220 |
Why?
| | Young Adult | 11 | 2025 | 13209 | 0.210 |
Why?
| | Adolescent | 11 | 2025 | 21513 | 0.210 |
Why?
| | Heterocyclic Compounds, 2-Ring | 1 | 2023 | 12 | 0.210 |
Why?
| | Thiadiazoles | 1 | 2023 | 23 | 0.200 |
Why?
| | Ezetimibe | 1 | 2022 | 24 | 0.200 |
Why?
| | Pregnancy in Diabetics | 1 | 2024 | 123 | 0.200 |
Why?
| | Stakeholder Participation | 1 | 2023 | 78 | 0.200 |
Why?
| | Insurance Coverage | 1 | 2024 | 230 | 0.200 |
Why?
| | Insurance, Health | 1 | 2024 | 283 | 0.190 |
Why?
| | Decision Making | 4 | 2019 | 900 | 0.190 |
Why?
| | Glomerular Filtration Rate | 2 | 2017 | 746 | 0.180 |
Why?
| | Food Microbiology | 1 | 2021 | 66 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2020 | 1477 | 0.170 |
Why?
| | Treatment Outcome | 9 | 2022 | 10811 | 0.170 |
Why?
| | Retrospective Studies | 9 | 2024 | 15657 | 0.170 |
Why?
| | Models, Econometric | 2 | 2018 | 34 | 0.170 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 179 | 0.170 |
Why?
| | Cholesterol, LDL | 1 | 2022 | 365 | 0.170 |
Why?
| | Eicosapentaenoic Acid | 1 | 2020 | 39 | 0.170 |
Why?
| | Patient Participation | 1 | 2024 | 420 | 0.160 |
Why?
| | Fees, Medical | 1 | 2019 | 9 | 0.160 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2844 | 0.160 |
Why?
| | Perception | 1 | 2022 | 359 | 0.160 |
Why?
| | Teicoplanin | 1 | 2019 | 15 | 0.160 |
Why?
| | Phthalazines | 1 | 2019 | 45 | 0.150 |
Why?
| | Indazoles | 1 | 2019 | 69 | 0.150 |
Why?
| | Early Diagnosis | 1 | 2020 | 242 | 0.150 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2019 | 70 | 0.150 |
Why?
| | Aged, 80 and over | 4 | 2025 | 7635 | 0.140 |
Why?
| | Antigens, CD19 | 1 | 2019 | 123 | 0.140 |
Why?
| | England | 1 | 2018 | 97 | 0.140 |
Why?
| | Rivaroxaban | 1 | 2020 | 255 | 0.140 |
Why?
| | Open Access Publishing | 1 | 2017 | 6 | 0.140 |
Why?
| | Parkinson Disease | 1 | 2024 | 493 | 0.140 |
Why?
| | Lymphoma, B-Cell | 1 | 2019 | 106 | 0.140 |
Why?
| | Piperidines | 1 | 2019 | 206 | 0.140 |
Why?
| | Diabetic Ketoacidosis | 1 | 2020 | 201 | 0.140 |
Why?
| | Dry Powder Inhalers | 1 | 2017 | 2 | 0.140 |
Why?
| | Peer Review, Research | 1 | 2017 | 43 | 0.140 |
Why?
| | Heparin | 1 | 2019 | 261 | 0.130 |
Why?
| | Metered Dose Inhalers | 1 | 2017 | 16 | 0.130 |
Why?
| | Data Collection | 1 | 2020 | 673 | 0.130 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 2129 | 0.130 |
Why?
| | Pilot Projects | 1 | 2022 | 1710 | 0.130 |
Why?
| | Aspirin | 1 | 2020 | 387 | 0.130 |
Why?
| | Hospitalization | 4 | 2024 | 2199 | 0.130 |
Why?
| | Piperazines | 1 | 2019 | 350 | 0.130 |
Why?
| | Feasibility Studies | 1 | 2020 | 956 | 0.130 |
Why?
| | Economics, Pharmaceutical | 1 | 2016 | 9 | 0.130 |
Why?
| | Models, Statistical | 1 | 2020 | 669 | 0.130 |
Why?
| | Medication Errors | 1 | 2017 | 95 | 0.130 |
Why?
| | Antirheumatic Agents | 1 | 2019 | 293 | 0.120 |
Why?
| | Sepsis | 1 | 2022 | 617 | 0.120 |
Why?
| | Indoles | 1 | 2019 | 412 | 0.120 |
Why?
| | Hematologic Neoplasms | 1 | 2018 | 156 | 0.120 |
Why?
| | Quality of Life | 3 | 2024 | 2892 | 0.120 |
Why?
| | Spirometry | 1 | 2016 | 281 | 0.120 |
Why?
| | Alzheimer Disease | 1 | 2021 | 560 | 0.120 |
Why?
| | Information Dissemination | 1 | 2017 | 218 | 0.120 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 289 | 0.120 |
Why?
| | Telemedicine | 1 | 2024 | 862 | 0.110 |
Why?
| | Venous Thromboembolism | 1 | 2019 | 316 | 0.110 |
Why?
| | Intellectual Property | 3 | 2019 | 10 | 0.110 |
Why?
| | Eosinophils | 1 | 2016 | 332 | 0.110 |
Why?
| | Child | 6 | 2025 | 21935 | 0.110 |
Why?
| | Canada | 1 | 2015 | 418 | 0.110 |
Why?
| | Child, Preschool | 3 | 2020 | 11074 | 0.110 |
Why?
| | Anticoagulants | 1 | 2019 | 664 | 0.110 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2014 | 59 | 0.110 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2014 | 65 | 0.110 |
Why?
| | Computer Simulation | 1 | 2018 | 978 | 0.100 |
Why?
| | Observational Studies as Topic | 1 | 2014 | 117 | 0.100 |
Why?
| | Sex Factors | 2 | 2017 | 2071 | 0.100 |
Why?
| | JC Virus | 1 | 2013 | 23 | 0.100 |
Why?
| | Fasting | 1 | 2014 | 281 | 0.100 |
Why?
| | Ergocalciferols | 1 | 2012 | 13 | 0.100 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1289 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2019 | 951 | 0.100 |
Why?
| | Diabetes Complications | 1 | 2014 | 227 | 0.090 |
Why?
| | Age Factors | 2 | 2017 | 3295 | 0.090 |
Why?
| | Comorbidity | 2 | 2014 | 1622 | 0.090 |
Why?
| | Analysis of Variance | 1 | 2014 | 1316 | 0.090 |
Why?
| | Income | 1 | 2012 | 202 | 0.090 |
Why?
| | International Classification of Diseases | 2 | 2022 | 135 | 0.090 |
Why?
| | Unemployment | 1 | 2010 | 43 | 0.090 |
Why?
| | Diabetic Nephropathies | 1 | 2014 | 294 | 0.080 |
Why?
| | Prescription Drugs | 1 | 2012 | 109 | 0.080 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2019 | 718 | 0.080 |
Why?
| | Diagnostic Tests, Routine | 1 | 2011 | 110 | 0.080 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 186 | 0.080 |
Why?
| | Arthritis, Rheumatoid | 1 | 2019 | 1167 | 0.080 |
Why?
| | Databases, Factual | 1 | 2015 | 1357 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1809 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2020 | 2057 | 0.070 |
Why?
| | Epilepsy | 1 | 2012 | 333 | 0.070 |
Why?
| | Vitamin D | 1 | 2012 | 397 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 890 | 0.070 |
Why?
| | Depressive Disorder | 1 | 2010 | 379 | 0.070 |
Why?
| | Uncertainty | 2 | 2019 | 128 | 0.070 |
Why?
| | Multiple Sclerosis | 1 | 2011 | 455 | 0.060 |
Why?
| | Follow-Up Studies | 1 | 2015 | 5131 | 0.060 |
Why?
| | Cohort Studies | 4 | 2019 | 5742 | 0.060 |
Why?
| | Hemorrhage | 2 | 2020 | 722 | 0.060 |
Why?
| | Cost Savings | 1 | 2024 | 84 | 0.060 |
Why?
| | C-Peptide | 1 | 2025 | 163 | 0.050 |
Why?
| | Demography | 1 | 2024 | 291 | 0.050 |
Why?
| | Neurologists | 1 | 2024 | 21 | 0.050 |
Why?
| | Infant | 2 | 2015 | 9465 | 0.050 |
Why?
| | Sexual Partners | 1 | 2024 | 186 | 0.050 |
Why?
| | Recurrence | 2 | 2018 | 1060 | 0.050 |
Why?
| | Glatiramer Acetate | 2 | 2013 | 18 | 0.050 |
Why?
| | Stress, Psychological | 1 | 2010 | 1100 | 0.050 |
Why?
| | Pregnancy | 2 | 2024 | 6763 | 0.050 |
Why?
| | Massachusetts | 1 | 2022 | 172 | 0.050 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 257 | 0.050 |
Why?
| | Risk Factors | 3 | 2024 | 10388 | 0.040 |
Why?
| | Menopause | 1 | 2023 | 320 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2019 | 76 | 0.040 |
Why?
| | Off-Label Use | 1 | 2019 | 52 | 0.040 |
Why?
| | Receptors, Interleukin-6 | 1 | 2019 | 43 | 0.040 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 80 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2018 | 94 | 0.040 |
Why?
| | Population Surveillance | 1 | 2021 | 482 | 0.040 |
Why?
| | Drug Approval | 1 | 2018 | 88 | 0.030 |
Why?
| | Palliative Care | 1 | 2024 | 758 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2019 | 200 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2019 | 190 | 0.030 |
Why?
| | Pulmonary Embolism | 1 | 2019 | 226 | 0.030 |
Why?
| | Asia | 1 | 2016 | 71 | 0.030 |
Why?
| | Peptides | 2 | 2013 | 985 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2017 | 233 | 0.030 |
Why?
| | Medicine | 1 | 2017 | 121 | 0.030 |
Why?
| | HIV Infections | 2 | 2024 | 2836 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1325 | 0.030 |
Why?
| | Incidence | 1 | 2022 | 2804 | 0.030 |
Why?
| | Policy Making | 1 | 2016 | 98 | 0.030 |
Why?
| | Biological Products | 1 | 2019 | 216 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2017 | 688 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2014 | 148 | 0.030 |
Why?
| | Hospitals | 1 | 2019 | 691 | 0.030 |
Why?
| | Cystatin C | 1 | 2014 | 65 | 0.030 |
Why?
| | Probability | 1 | 2014 | 304 | 0.030 |
Why?
| | Length of Stay | 1 | 2019 | 1215 | 0.030 |
Why?
| | Propylene Glycols | 1 | 2013 | 28 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2024 | 6079 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2019 | 827 | 0.030 |
Why?
| | Fingolimod Hydrochloride | 1 | 2013 | 40 | 0.020 |
Why?
| | Sphingosine | 1 | 2013 | 46 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2016 | 565 | 0.020 |
Why?
| | Critical Illness | 1 | 2019 | 811 | 0.020 |
Why?
| | Health Policy | 1 | 2016 | 388 | 0.020 |
Why?
| | Vascular Calcification | 1 | 2014 | 108 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1793 | 0.020 |
Why?
| | Drug Evaluation | 1 | 2012 | 84 | 0.020 |
Why?
| | Linear Models | 1 | 2014 | 849 | 0.020 |
Why?
| | Efficiency | 1 | 2012 | 99 | 0.020 |
Why?
| | Health Services | 1 | 2012 | 107 | 0.020 |
Why?
| | Mitoxantrone | 1 | 2011 | 14 | 0.020 |
Why?
| | Hematologic Tests | 1 | 2011 | 22 | 0.020 |
Why?
| | Interferon-beta | 1 | 2011 | 92 | 0.020 |
Why?
| | Employment | 1 | 2012 | 178 | 0.020 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 97 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 6828 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2011 | 600 | 0.020 |
Why?
| | Health Surveys | 1 | 2010 | 514 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 1040 | 0.020 |
Why?
| | Electrocardiography | 1 | 2011 | 629 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2010 | 786 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1430 | 0.010 |
Why?
| | Electronic Health Records | 1 | 2012 | 1069 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3566 | 0.010 |
Why?
|
|
McQueen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|